Bayer
拜耳
Bayer appears in elsewhere's corpus primarily as a reference point for executives who left to found Chinese healthcare and biotech ventures. In a 2023 interview with 5Y Capital, Sihui Ma Xuguang described departing Bayer to start Sipai Health, seeking to move beyond pharmaceutical marketing toward a broader view of patient access and outcomes . The company's name also surfaces in a 2020 profile of Huanyi Biology, where scientific team members had previously served at "Roche, AstraZeneca, Bayer and other international giants" , and in a 2026 report on Aaru's simulation platform, which counts Bayer among its customers alongside McDonald's and EY . elsewhere's corpus does not contain a direct profile of Bayer as a corporate entity.
AI-generated — may contain errors, please verify.
Coverage
When a Billion AIs Simulate the Future Together: The New Bet Fei-Fei Li and Karpathy Are Both Making | 5Y Research
When One Billion AIs Simulate the Future Together: A New $1 Billion Series A Track, Co-Bet by Fei-Fei Li and Karpathy
五源资本·Medicine Is the Science of Uncertainty and the Art of Possibility | 5Y Talk × Sihui Ma Xuguang
Illness is part of being human, and humans are part of society.
五源资本·Linear Capital News | Linear Capital-led Pre-A round portfolio company "Akenong" announces over 100 million RMB funding round, with Linear Capital continuing to increase its support
On June 23, 2022, Aicron, China's first smart crop cultivation decision-making service provider, announced the completion of two consecutive funding rounds — a Series A and a Series A+ — totaling over RMB 100 million. The Series A was led by Source Code Capital, while the Series A+ was jointly led by IDG Capital and Hillhouse. Linear Capital and Bits x Bites participated in both rounds as co-investors.
线性资本·5Y News｜Vivace Therapeutics Announces Completion of Angel Round Raising Tens of Millions of RMB
Huanyi Bio announced the completion of an angel funding round of tens of millions of RMB, led by 5Y Capital.
五源资本·
